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ABSTRACT

THE EFFECT OF IN VIVO PBDE TREATMENT ON
HEPATIC PHOSPHOENOLPYRUVATE CARBOXYKINASE (PEPCK)
ENZYME KINETICS IN MALE WISTAR RATS

by

Jessica T. Nash
University of New Hampshire, September 2011
Polybrominated diphenyl ethers (PBDEs) are synthetic flame-retardant chemicals
that enter the environment and mammalian body and may disrupt glucose metabolism.
This study investigated the effect of PBDEs on a key gluconeogenic enzyme,
phosphoenolpyruvate carboxykinase (PEPCK). Forty-eight male Wistar rats were
gavaged with corn oil or corn oil containing 14 mg/kg DE-71 for 3, 14 or 28 days (N = 8
per group). At each time point, fasting plasma glucose, insulin and C-peptide were
measured and liver PEPCK enzyme activity was assayed. PBDEs significantly decreased
PEPCK Vmax (u.mol/min/g liver weight) at 3 days by 26%; this reduction persisted
through 28 days. PBDEs also reduced total PEPCK activity (jj.mol/min/liver) by 18% (3
days) to 41% (28 days). Fasting plasma glucose levels remained unaffected by PBDE
treatment. Findings demonstrate that PBDEs reduce hepatic PEPCK Vmax as early as
three days of treatment; the implications for this reduction in glucose homeostasis remain
to be determined.

x

CHAPTER I

LITERATURE REVIEW

Preface
This literature review is divided into five sections: chemical and physical
properties of PBDEs including general characteristics, environmental presence and routes
of exposure; metabolism of PBDEs including information about drug metabolizing
enzymes; the metabolic effects of PBDEs including endocrine disruption and cytochrome
P450 enzyme induction; the mechanism of PBDE action including PBDEs binding as a
ligand to nuclear receptors; and phosphoenolpyruvate carboxykinase (PEPCK),
xenobiotics and PBDEs including information about PEPCK activity following
xenobiotic exposure.
Chemical and Physical Properties of PBDEs
Polybrominated diphenyl ethers (PBDEs) are a family of lipophilic, flame
retardant chemicals introduced in the 1970's. PBDEs are used in consumer products
including plastics, electronics, furniture and carpeting to slow the rate at which products
burn. The structure of PBDEs is two phenyl rings attached by an ether bridge (Figure 1).
The number of bromine atoms found on the phenyl rings can vary, generating 209
possible congeners (Darnerud et al. 2001). The three most common industrial mixtures
are penta-BDE, used mostly in furniture, and deca-BDE and octa-BDE, used mostly in
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electronics (Hale et al. 2003; McDonald 2002). Penta-BDEs contain 3 to 6 bromine
atoms and include the congeners BDE-47, -99, -100, -153, -154 and -85. Octa-BDEs
contain 6 to 8 bromine atoms and include the congeners BDE-183 and -153. Deca-BDEs
contain 8 to 10 bromine atoms and include the congener BDE-209 (Hale et al. 2003).
Figure 1: General structure of PBDEs

T

n
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Figure 1: General structure of PBDEs. Location and number of bromine atoms
theoretically forms 209 different congeners (Darnerud et al. 2001).
PBDEs can be incorporated in consumer products in one of two ways: via a
chemical reaction or as an additive. When the flame retardant is chemically reacted with
a product, a covalent bond is formed between the flame retardant and product making the
PBDEs less likely to leach into the environment. Additive PBDEs are only mixed with
the polymer resin. Therefore, as products break down, additive PBDEs have the ability to
leach into the environment because they are not chemically bound to the product
(Darnerud et al. 2001; Kim et al. 2006; McDonald 2002).
PBDEs are resistant to chemical and physical breakdown, therefore, once in the
environment, they can bioaccumulate and even biomagnify within the food chain (Alaee
and Wenning 2002; Costa et al. 2008; Hale et al. 2003). Originally, it was thought that
deca-BDE was less bioaccumulative compared to other lower brominated congeners due
to being fully brominated, poorly absorbed, rapidly excreted and having a high molecular

2

weight (McDonald 2002); (Huwe 2005; Norris et al. 1975). However, when exposed to
ultraviolet light, deca-BDE can be converted to lower brominated congeners, increasing
its bioaccumulative ability (Watanabe et al. 1987).
Environmental Presence
Since their introduction in the 1970s, PBDEs have been found in the environment
and organisms worldwide including soil sediment, marine animals, fish-eating birds,
human breast milk, serum and adipose tissue. In 1981, it was discovered that fish from
the Viskan River in Sweden had PBDEs in their tissues (Andersson and Blomkviet 1981).
In 1983, it was found that bird tissues from several U.S. locations and Ontario, Canada
also contained PBDEs (Stafford 1983). PBDEs were found in fish-eating birds and
marine animals in the Arctic region and in the same year, Watanabe et al., confirmed the
same findings in the Pacific region (Jansson et al. 1987; Watanabe et al. 1987). More
recently, PBDEs have been detected in human tissues including breast milk, serum and
adipose, with levels in North Americans reportedly two to ten times higher than levels in
Europeans and Asians (Dunn et al. 2010; Inoue et al. 2006; Lorber 2008; Petreas et al.
2003; Schecter et al. 2003).
Routes and Sources of Exposure
There are three major routes of PBDE exposure: inhalation, dermal absorption
and ingestion. Dust can serve as a PBDE source for all three routes. Indoor house dust
was analyzed in cities in Canada, New Zealand, United Kingdom and United States and
showed median concentrations of PBDEs ranging from 59 to 2,800 ng/g (Harrad et al.
2008). A positive correlation was found between the levels of PBDEs in house dust and
the levels of PBDEs in breast milk of mothers in Massachusetts (Wu et al. 2007).
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Dust not only accounts for exposure via inhalation but also via dermal absorption
(Lorber 2008). Blood samples from computer-dismantle workers in Sweden contained a
variety of PBDEs. Congener BDE - 183 was the highest detected at 7.8 ng/g lipid weight
whereas the control group had only 0.12 ng/g lipid weight (Sjodin et al. 1999). However,
one in vitro study showed that only 3.13% of an applied dose of tetrabromodiphenyl ether
was absorbed through human skin membranes and concluded that the risk of dermal
absorption of PBDEs is lower than via inhalation and ingestion (Roper et al. 2006).
Diet acts as another source of exposure to PBDEs. PBDEs have been found in a
variety of marine animals consumed by humans, but they have also been detected in dairy
products. A survey of various foods in the United States have shown a total concentration
of greater than 6,000 pg/g in butter and over 900 pg/g and 1,000 pg/g in salmon and
canned sardines, respectively. PBDE congener BDE-47 was detected in 30 of the 31 food
samples tested and BDE-99 was detected in 28 of 31 food samples (Schecter et al. 2010).
Breast milk has been analyzed in the U.S. with median levels ranging from 6.1 419 ng/g lipid (Schecter et al. 2003). Breast milk also serves as a source of PBDE
exposure in infants. One case study analyzed serum levels of PBDEs in a family of four.
The researchers found that the breast-fed infant had serum PBDE levels two to five times
higher than his parents (Fischer et al. 2006). The sum of 6 PBDE congeners measured
was 418 ng/g lipid weight (lw), while the toddler had 247 ng/g lw, mother 106 ng/g lw
and the father 64 ng/g lw. The researchers concluded that the two to five-fold differences
in PBDE levels seen in the younger children could be attributed to breast milk and dust as
main sources of exposure for the infant and toddler, respectively.
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Metabolism of PBDEs
Once in the body, the target organs for PBDE toxicity are the liver, kidney and
thyroid gland (Costa et al. 2008). One study sought to explore the level of toxicity of
BDE-209 in neonatal rats. Sprague-Dawley rats were administered 100-600 mg of BDE209/kg body weight daily from postnatal day (PND) 10 to PND 46. Hypertrophy of the
liver and thyroid gland, as absolute weight, were seen in the high dose group (Lee et al.
2010).
Another study investigated the toxicity of DE-71, a commercial mixture of mostly
penta-BDE congeners. Male and female F344/N rats and B6C3F1 mice were
administered a range of 0 - 500 mg/kg/day for 5 days/week for 13 weeks. The
researchers found an increase in liver weights and liver lesions of rats receiving doses of
5 mg/kg or higher and mice receiving 50 mg/kg or higher. They also saw hepatocyte
hypertrophy in both rats and mice receiving doses of 50 mg/kg or higher (Dunnick and
Nyska 2009).
Metabolism studies of PBDEs have been mostly limited to rodents, von
Meyerinck et al. (1990) administered a single dose of 300 mg/kg of Bromkal-70, a
commercial mixture of penta-BDEs, to male and female rats. The highest concentration
was seen in the adipose tissue four days after exposure (von Meyerinck et al. 1990). Orn
and Klasson-Wehler demonstrated that after a single dose of 14.5 mg/kg body weight of
14

C-labeled BDE-47, 86% remained in the adipose, liver, lung, kidney, brain and plasma

after 5 days while only 14% was excreted through the feces and <0.5% was excreted
through the urine. The highest concentration was found to be in the adipose tissue (Orn
and Klasson-Wehler 1998).
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It has been shown PBDE metabolites can form within the body. The majority of
metabolites found in the previous study were hydroxylated compounds: ortho-OHtetrabromoDE, weta-OH-tetrabromoDE and />ara-OH-tetrabromoDE (Orn and KlassonWehler 1998). The purpose of adding an -OH group is to create a more hydrophilic
compound making excretion of the toxin more feasible.
Cytochrome P-450
The detoxification of xenobiotics, specifically aromatic or aliphatic compounds
such as PBDEs, occurs with the insertion of an oxygen atom (Poulos 1988, 2005).
R - H + 0 2 + 2e " ^ R - O H
A majority of hydroxylation occurs in the liver via drug metabolizing enzymes. One
specific family of drug metabolizing enzymes is cytochrome P450 (CYP). There are 22
known gene families of CYPs in mammals, denoted as CYPl, CYP2, CYP3 etc. and
subfamilies denoted as CYP1A, CYP1B, CYP1C, etc. (Hakk and Letcher 2003; Nelson et
al. 1996). The CYPl, CYP2 and CYP3 families are responsible for the majority of
detoxification of xenobiotics (Nedelcheva and Gut 1994). CYPs are comprised of a single
polypeptide chain containing a noncovalently bound heme. CYPs are between 45,000 and
55,000 Daltons and are highly expressed in the liver and intestines (Poulos 1988, 2005).
Metabolic Effects of PBDEs
Many studies have demonstrated an increase of CYP gene expression and enzyme
activity following exposure to PBDEs. It has been reported that the minimum dose of
PBDEs necessary to induce CYPs ranges 3 - 1 0 mg/kg (Hakk and Letcher 2003).
Sanders et al. (2005) administered treatments via gavage of DE - 71, PCBs and
individual congeners of PBDEs in varying amounts of 0.005 - 150 mg/kg/day to male
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F344 rats for 3 days. DE - 71 up-regulated gene expression of CYP1A1 by up to 3500fold at 150 mg/kg/day. When congeners BDE-47, -99 and -153 were administered
between 57 and 150 mg/kg/day, CYP1A1 gene expression increased by 2.4, 8.1 and 19fold, respectively. Similar increase of gene expression was seen for CYP2B and CYP3A
(Sanders et al. 2005). Exposure of human hepatocytes to BDE-99 and BDE-209 increased
gene expression of CYP1A2 by up to 2 x 105 fold, and CYP3A4 up to 10 fold (Stapleton
et al. 2009). A significant increase (fold increase was not reported) in protein expression
of CYPl A2, CYP3A1 and CYP2B1 was also observed in a study that administered doses
of 100, 300 or 600 mg/kg body weight of BDE-209 (Lee et al. 2010).
PBDEs have been categorized as endocrine disrupting chemicals as they interfere
with hormones including thyroid and the estrogen family. Hallgren and Darnerud (2002)
found that free thyroxine (T4) was decreased by 61% compared to control rats following
exposure to BDE-47 (Hallgren and Darnerud 2002). Zhou et al. (2001) found that
weanling female rats, when exposed to varying commercial mixtures of PBDEs for 4
days, had a dose-dependent decrease in total thyroxine (T4) (Zhou et al. 2001). The same
researchers found that exposing pregnant female rats to the commercial penta mixture of
PBDEs, DE-71, also decreased total T4 levels in the fetuses in a dose-dependent manner
(Zhou et al. 2002).
Studies have also demonstrated the ability of PBDEs to disrupt estrogen
homeostasis. In one study, breast cancer cells and ovarian cancer cells were exposed to
DE-71 and six synthesized hydroxylated PBDE metabolites. DE-71 failed to displace
estradiol from the estrogen receptor alpha (ER-a), however, all six hydroxylated
metabolites were able to displaced estradiol binding from ER-a (Mercado-Feliciano and
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Bigsby 2008). Another study treated pregnant Wistar rats with 140 or 700 [xg/kg body of
BDE-47 beginning on gestation day 6 through postnatal day 21. The researchers found a
significant decrease in ovarian weight in the lower dose group and a decrease in serum
estradiol concentrations in the higher dose group. (Talsness et al. 2008)
PBDEs have also been implicated in disrupting adipocyte metabolism. Male
Sprague-Dawley rats were gavaged 14 mg/kg of a penta-BDE mixture daily for 2 and 4
weeks. Adipocytes were isolated and lipolysis and glucose oxidation was measured.
Isoproterenol-induced lipolysis was 30% higher and insulin-stimulated glucose oxidation
was 59% lower in cells of 4 week- treated rats compared to control (Hoppe and Carey
2007).
Mechanism of PBDE Action
Similar to many other xenobiotics, PBDEs act by binding to nuclear receptors
(NRs). NRs are a family of transcription factors that can be activated by a number of
ligands including pharmaceutical drugs, endogenous compounds and environmental
chemicals. Some examples of NRs include constitutive androstane receptor (CAR),
pregnane X receptor (PXR) and aryl hydrocarbon receptor (AhR). Xenobiotics, such as
PBDEs, will enter a cell either by passive diffusion or active transport and can bind to
NRs in the cytosol (Figure 2). Once bound by a ligand, the nuclear receptor-xenobiotic
compound will enter the nucleus. The nuclear receptor will form a heterodimer with other
receptors, such as retinoid X receptor (RXR), and bind to a response element on the
DNA, triggering gene transcription and, eventually, translation of the corresponding CYP
enzyme (Hewitt et al. 2007; Tompkins and Wallace 2007).
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Figure 2: Cell model of CYP Induction

Figure 2: General induction process of the drug metabolizing enzymes, CYPs, via gene
transcription following exposure to a xenobiotic. (Denoted in the figure as "xeno";
adapted from (Hewitt et al. 2007).
PBDEs as a Ligand
PBDEs have been confirmed as ligands and activators of PXR, but not for CAR
or AhR (Sakai et al. 2009; Wahl et al. 2010). Pacyniak et al. (2007) used human HepG2
cells and transfected them with a number of plasmids including cDNA for mouse PXR
bound to luciferase vectors. Cells were exposed to PBDEs for 24-hours. Luciferase
activity significantly increased in a dose-dependent response to varying PBDE congeners
demonstrating that PBDEs bind as a ligand to PXR.
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The researchers wanted to explore if there was a similar response in vivo and used
two groups of mice, wild type and PXR knockout, to investigate this question. The mice
were injected with a mixture of 100 mg/kg/day of BDE-47, -99, and -209 for 4 days.
There was an increase in CYP3A and 2B RNA and protein by 2 to 2.5 fold in the wild
type, as expected, and an increase, but to a lesser degree, of the same CYP RNA and
protein in the PXR knockout mice. The authors suggested that there might be other ways
in which PBDEs induce CYPs (Pacyniak et al. 2007).
In a similar study, human HepG2 and rat hepatoma H4IIE cells were transfected
with an XREM reporter gene (a plasmid that is transactivated by PXR) containing
luciferase as the reporter. Cells were exposed to a technical mixture of pentaBDEs for 48
hours. The pentaBDE mixtures increased CYP3A1 and CYP3A4 mRNA by 1 to 4 fold in
both cell types (Fery et al. 2009), demonstrating that PBDEs act as a ligand for PXR in
human and rat liver cells in vitro.
PXR Crosstalks with Gluconeogenesis
PXR has direct transcriptional regulation over drug metabolizing enzymes but can
also crosstalk with other transcription factors to alter expression of other metabolic genes
involved in gluconeogenesis (GNG) (Ihunnah et al. 2011). GNG is the conversion of
substrates including lactate, glycerol and pyruvate, to glucose, as the brain needs a
constant supply of glucose to sustain function. GNG occurs during fasted states such as
overnight when no dietary glucose is being supplied. Consumption of a highcarbohydrate diet will slow GNG to cessation until the next fasted state. GNG is a
regulated process and the regulation is three-fold: via substrates, by hormones such as

10

insulin

and glucagon

and by

key

regulatory

enzymes,

one

of which

is

phosphoenolpyruvate carboxykinase (PEPCK) (Harvey and Ferrier 2011).
Studies have shown that activated PXR can repress specific genes found in the
GNG pathway, including PEPCK. Zhou et al. (2008) used wild type mice or transgenic
mice that expressed an activated form of PXR in the liver. In the transgenic mice, RNA
expression of PEPCK was reduced compared to the wild type (Zhou et al. 2006). Bhalla
et al. (2004) found similar results in vitro. HepG2 cells were transfected with human PXR
vector and then exposed to 10 uM rifampicin, a known PXR ligand, or dimethyl
sulfoxide (Me2SO) as control for 24 hours. RNA expression of PEPCK was decreased in
the rifampicin-treated cells compared to cells treated with Me2SO (Bhalla et al. 2004).
These results demonstrate that when PXR is activated, PEPCK gene expression is
suppressed.
PEPCK. Xenobiotics and PBDEs
Phosphoenolpyruvate Carboxykinase (PEPCK)
PEPCK converts oxaloacetate to phosphoenolpyruvate and uses guanosine
triphosphate (GTP)- or inosine triphosphate (ITP)- as a co-substrate (Figure 3). PEPCK is
present in the liver, kidney, lung, heart, small intestine and adipose tissue and resides in
both the mitochondria and cytosol of most mammals, although subcellular distribution
varies by species. For example, in humans, 60% of PEPCK is found in the mitochondria
with 40% in the cytosol. In rats, only 10% is found in the mitochondria while 90% is in
the cytosol (Hanson and Garber 1972; Hanson and Reshef 1997).
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Cytosolic PEPCK is highly regulated by diet and hormones including thyroid
hormone, glucagon, glucocorticoids and insulin. During fasting, activity of cytosolic
PEPCK increases by two- to eight-fold while the mitochondrial isoform remains virtually
Figure 3: Gluconeogenesis Pathway
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Figure 3: The pathway of gluconeogenesis showing PEPCK (circled), dependent on
GTP, to convert oxaloacetate to phosphoenolpyruvate (PEP) (King 2011).
unaffected, suggesting distinct isoform regulation (Ballard and Hanson 1969; Hanson and
Reshef 1997). In animals with predominant mitochondrial isoforms of PEPCK,
oxaloacetate (OAA) that is generated in the mitochondria via pyruvate carboxylase can
be converted to phosphoenolpyruvate (PEP). However, due to the poor permeability of
OAA in the mitochondria, animals that have the dominant form of PEPCK located in the
cytosol, must first convert OAA to malate and transport malate into the cytosol. Once in
the cytosol, malate is oxidized to OAA by malate dehydrogenase (MDH) where the
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cytosolic form of PEPCK can then convert OAA to PEP (Hanson and Reshef 1997). The
cytosolic form of PEPCK in the rat liver consists of 621 amino acids, has a molecular
weight of 69 kD (Beale et al. 1985) and a half-life of 6-8 hours (Ballard et al. 1974).
Other Roles of PEPCK
PEPCK is also present in nongluconeogenic tissues and, in the case of adipose
tissue and small intestine, is proposed to aid in providing glycerol backbone for
triglyceride synthesis via the process of glyceroneogenesis. (Hanson and Reshef 1997;
Reshef et al. 1970) Another role of PEPCK is cataplerosis or removal of citric acid cycle
anions.

Hakimi et al. (2005) evaluated the metabolic consequences of deleting the

cytosolic form of PEPCK (PEPCK-C) in the liver and kidney of mice in utero. [Fetal
livers do not contain PEPCK, as glucose is provided by the mother, but it appears at birth
corresponding to the needs of glucose production (Hanson and Reshef 1997)]. Mice were
killed two or three days after birth. The PEPCK knockout mice did not gain weight one
day after birth. Blood glucose levels in PEPCK knockout mice were 60% lower than
controls. Lipid accumulated in the liver of the PEPCK knockout mice and the triglyceride
level in the liver was twice the amount of controls. The same elevated level of
triglycerides was also seen in the blood of PEPCK knockout mice. The blood
concentration of (3-hydroxybutyrate, a ketone body, was three times higher than control,
and the levels of malate and lactate were 10 and 2.5 times higher, respectively, than
control (Hakimi et al. 2005). These results show the importance of PEPCK, not only in
the process of GNG, but also in maintaining homeostasis of energy metabolism.
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Regulation of PEPCK
The gene for PEPCK-C is regulated at the transcriptional level via induction and
repression. During times of starvation, PEPCK-C is induced and consumption of a high
carbohydrate diet will reduce PEPCK synthesis. Glucagon, a hormone released during
times of low blood sugar, and thyroid hormone both increase PEPCK-C synthesis while
insulin, released during times of high blood sugar, inhibits PEPCK-C synthesis (Ballard
and Hanson 1967; Gurney et al. 1994; Hanson and Reshef 1997).
The mechanism of glucagon induction involves glucagon binding to its surface
receptor, which stimulates Gs-protein. Stimulated G-protein will then stimulate adenylyl
cyclase causing an increase in cAMP levels. The increase in cAMP levels causes a
phosphorylation of protein kinase A (PKA). Activated PKA then phosphorylates cAMP
regulatory element binding protein (CREB), which binds to cAMP response element-1
(CRE-1). CRE-1 is located in Region 1 of the PEPCK-C gene promoter and is in close
proximity to the start location of transcription (Roesler et al. 1988, 1989; Yabaluri and
Bashyam 2010). If PEPCK mRNA is not translated, existing PEPCK mRNA will be
degraded with a half-life of about 40 minutes (Cimbala et al. 1982). However, the
presence of cAMP stabilizes PEPCK mRNA and extends the half-life to 140-250 minutes
(Hod and Hanson 1988). In contrast, glucocorticoids and thyroid hormone diffuse
through the plasma membrane and bind to receptors located in the cytosol. The occupied
receptors translocate into the nucleus and bind to glucocorticoid response elements
(GRE1 or -2) and a thyroid response element (TRE) on the PEPCK gene promoter,
respectively (Yabaluri and Bashyam 2010), to promote PEPCK transcription.
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Insulin acts in an opposing mechanism to glucagon. The presence of insulin
decreases the levels of cAMP causing PKA to remain inactive and does not
phosphorylate CREB (Harvey and Ferrier 2011). Insulin can also phosphorylate a
forkhead transcription factor (FOXOl) that normally is responsible for activating the
PEPCK gene. Phosphorylation of FOXOl renders it inactive by decreasing FOXOl's
binding affinity to the insulin response sequence (IRS) (O'Brien et al. 1995; Zhang et al.
2006), removing PEPCK gene activation.
Xenobiotic Effects on GNG and PEPCK
The effect of PBDE exposure in vivo and in vitro on GNG and PEPCK is
currently unknown. However, studies using other xenobiotic compounds have examined
effects on GNG and PEPCK. Male Wistar rats were administered an oral dose of 100
mg/kg/day of Phenobarbital, a pharmaceutical drug used to treat epilepsy and diabetes,
for 15 days. Hepatocytes were isolated and exposed to gluconeogenesis precursors
lactate/pyruvate, alanine, glycerol and glutamine. Glucose production was inhibited by
50% and PEPCK activity was also inhibited by 50% (Argaud et al. 1991). Chauvin et al.
(1996) found hepatic PEPCK enzyme kinetics from Phenobarbital-treated rats,
lOOmg/kg/day for 14 days was altered: Vmax and Km was reduced by about 50% and
30%, respectively. The researchers also determined the effect of Phenobarbital treatment
on PEPCK activity was post-translational as PEPCK protein and mRNA did not decrease
(Chauvin et al. 1996).
Viluksela et al. (1999) administered oral dosages of 2,3,7,8-tetrachlorodibenzo-/?dioxin (TCDD), a compound present in Agent Orange, ranging from 50 to 9600
ug/kg/day to male and female Han/Wistar rats for 10 days. PEPCK activity decreased in
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a dose-dependent manner with the highest dose of TCDD reducing maximal activity by
about 50% in males and 25% in females. Plasma glucose levels were also slightly
decreased compared to controls (Viluksela et al. 1999), suggesting that TCDD represses
PEPCK activity and, as a result, alters glucose homeostasis.
Vijayan et al. (2006) used Anadromous arctic char, a fish that resides in Arctic
bodies of water, and administered 0 or 100 mg/kg/day of Aroclor 1254, a commercial
polychlorinated biphenyl (PCB) mixture, for 4 months. The researchers treated two
groups of fish but fasted one group to mimic the natural fasting pattern seen during the
winter months and continuously fed another group for comparison. Results showed a
55% reduction in plasma glucose and a 66% reduction of PEPCK activity in the 100
mg/kg fasted group compared to both the 0 mg/kg fasted group and the 100 mg/kg fed
group (Vijayan et al. 2006). These data suggest that, in fish, PCB not only reduces
PEPCK activity but also inhibits glucose production in the fasted, but not fed, state.
Summary
PBDE treatment has been shown to increase hepatic CYP RNA, protein and
activity. PBDEs also act as a ligand and activator of the nuclear receptor, PXR. Animal
models with activated PXR have shown a decrease in hepatic PEPCK mRNA. It has been
established that exposure of animals to certain xenobiotics reduces activity of PEPCK,
the key enzyme found in the gluconeogenesis pathway. The effect of PBDE exposure of
rats on hepatic PEPCK activity is unknown.
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Hypothesis
The purpose of this study was to determine the effect of in vivo PBDE treatment
of rats on hepatic PEPCK activity and in vivo glucose homeostasis: it tested the
hypothesis that hepatic PEPCK activity is reduced by in vivo PBDE treatment of rats.
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CHAPTER II

MATERIALS AND METHODS

Animals
Forty-eight male Wistar rats, (Charles River Laboratory, Wilmington, MA) were
used for this study. All rats weighed between 75-100 grams upon arrival. The rats were
housed under controlled atmosphere and a 12- hour light/dark cycle. They were fed
standard chow and water ad libitum. The University of New Hampshire's Animal Care
and Use Committee approved all procedures, #110406.
Treatment
The rats were allowed to adjust to their new habitat for five days prior to the start
of treatment. The rats were randomly assigned to two different gavage treatments: 14 mg
PBDE / kg body weight / day (n = 24) or corn oil control (n = 24). Rats were gavaged
daily, generally between 8 and 9 am. Initial body weights were obtained at the onset of
treatment and body weight was recorded three times per week. Rats were euthanized after
a 16 - hour fast at 3, 14 and 28 days of treatment (n = 8), using carbon dioxide gas. (Gas
was allowed to fill the chamber for 90 seconds, followed by 90 seconds of no gas.)
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Solutions
PBDE Gavaging Solution
•

Two grams of DE - 71, a commercialized mixture of penta - PBDEs (Great
Lakes Chemical Corporation, West Lafayette, IN through a generous gift from Dr.
David Szabo) was removed from the original glass vial via a small metal spatula,
dissolved into 2400 ul of hexane in a secondary glass vial and vigorously mixed.
The mixture was placed in a 37°C water bath and stirred with a glass rod until
PBDEs were completely dissolved. The mixture was poured into an amber glass
bottle containing 60 ml of corn oil. An additional 51 ml of corn oil were added
and the bottle was vortexed for 30-60 seconds to mix contents thoroughly. The
hexane was evaporated under the hood using compressed nitrogen for 5 - 10
hours. The solution was stored in an amber bottle at room temperature.

Corn Oil Gavaging Solution
•

Hexane, 2400 ul, was added to 111 ml of corn oil in an amber bottle. The vial was
vortexed for 30-60 seconds to mix contents thoroughly. The hexane was then
evaporated using compressed nitrogen under the hood for 5 - 10 hours. The
solution was stored in an amber bottle at room temperature.
Preparation of Blood and Liver Samples

Blood
Rats were removed from the euthanasia chamber, the abdominal cavity was
spread and a lateral incision was made to expose the internal organs. The diaphragm was
then cut to expose the heart. Approximately 5 ml of blood was obtained via cardiac
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puncture using a 0.2% EDTA-rinsed 18G-1.5" needle attached to a 5 ml syringe. Blood
was transferred to a 6 ml EDTA - treated tube (Thermo Fisher Scientific, Waltham, MA)
and kept on ice until it was transported back to the lab. Once in the lab, the collected
blood was centrifuged at 3000 rpm for 15 minutes at 4°C in an IEC - Centra8R
centrifuge. Approximately 1-2.5 ml of plasma was removed, aliquoted into cryovials in
the amount of 250 - 400 ul, frozen and stored at -80°C.
Liver
The liver was removed, weighed, cut into approximately two-gram portions, flash
frozen in liquid nitrogen, wrapped in aluminum foil and stored at -80°C.
Preparation of Liver Cytosol Fraction

Liver cytosol fraction was prepared, with modifications, as described by Chauvin
et al. (1996). Liver was thawed, weighed (approx. 2 g), minced with scissors and placed
in nine volumes of working homogenizing solution (refer to Solutions). Tissue was then
homogenized for 15 seconds using a Powerstat® polytron (Thermo Fisher Scientific,
Waltham, MA) at a setting of 60.
Homogenized liver was centrifuged at 3116.425 x g (5000 rpm) for 15 minutes at
4°C in a Sorvall Evolution RC centrifuge. The supernatant was removed and centrifuged
at 59466 x g (30000 rpm) for 60 minutes at 4°C in a Beckman L8-80 ultracentrifuge.
Supernatant was removed, placed on ice and used for PEPCK enzyme-coupled assay
analysis. Total protein concentration of the supernatant was measured via a commercial
DC protein assay (BioRad, Hercules, CA).
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Solutions
Stock Solution of 0.5 M Potassium Phosphate, pH 7.0
•

The solution was made by placing 13.609 g of potassium phosphate (FW: 136.09)
into 150 ml ddH20. The pH was adjusted to 7 with NaOH and the final volume
was brought to 200 ml. Solution was stirred and stored at 4°C.

Stock Solution of 50 mM PMSF
•

The solution was made by placing 0.1742 g of PMSF (FW: 174.19) in 100%
ethanol with the final volume being brought to 20 ml. Solution was vortexed until
particles dissolved and stored at 4°C.

Stock Solution of 50 mM DTT
•

The solution was made by placing 0.154 g of DTT (FW: 154.25) in ddH20 with
the final volume being brought to 20 ml. Solution was stirred and stored at 4°C.

Stock Solution of 20 mM EDTA
•

The solution was prepared by placed 0.7368 g of EDTA (FW: 368.4) into ddH20
with the final volume being brought to 100 ml. The solution was stirred and
stored at 4°C.

Stock Solution of 0.5 mM Leupeptin
•

The solution was prepared by placing 0.0021 g of leupeptin (FW: 426.6) into
ddH20 with the final volume being brought to 10 ml. The solution was stirred,
aliquoted into cryovials (100 \x\) and frozen at -20°C.

Working Homogenizing Solution
•

Twelve milliliters of 0.5 M Potassium Phosphate stock solution, 1.2 ml of 50 mM
PMSF stock solution, 1.2 ml of 50 mM DTT stock solution, 3 ml of 20 mM
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EDTA stock solution and 120 ul of 0.5 mM leupeptin stock solution were mixed
with the final volume being brought to 60 ml with ddH 2 0. The final concentration
of the working homogenizing solution consisted of 0.1 M potassium phosphate,
pH 7; 1 mM PMSF; 1 mM DTT; 1 mM EDTA; and 1 uM leupeptin.
Analysis of Blood and Liver
Blood Analysis
Blood was analyzed for fasting glucose, insulin and C-peptide. Fasting glucose
was measured using a commercial glucose oxidase kit (Sigma-Aldrich, St. Louis, MO).
Insulin and C-peptide were measured using commercial ELISA and RIA kits,
respectively (Millipore, Billerica, MA).
Liver Cytosol Fraction
The liver cytosol was used for a Phosphoenolpyruvate Carboxykinase (PEPCK)
enzyme-coupled assay and was performed, with modifications, as described by Chauvin
et al. (1996). The enzyme-coupled assay utilizes malate dehydrogenase (MDH) to
convert

malate

to

oxaloacetate

(OAA).

PEPCK

then

converts

OAA

to

phosphoenolpyruvate (PEP). MDH requires nicotinamide adenine dinucleotide (NAD+)
as a coenzyme resulting in the generation of the reduced form of nicotinamide adenine
dinucleotide (NADH). (Figure 4) The presence of NADH can then be measured
spectrophotometrically at 340 nm.
A 3-ml acrylic cuvette contained the following: 12.5 mM Tris, pH 8.0; 0.75 mM
MnCl2; 1 mM NAD+; 6 U of malate dehydrogenase and varying amounts of malate (0,
0.125, 0.25, 0.375, 0.5, 1, 2, 4 and 8 mM), as shown in Table 1. The mixture was allowed
to equilibrate in a 37°C water bath for three minutes.
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Figure 4: PEPCK enzyme-coupled assay

MDH

PEPCK

malate <4

^

NAD+

OAA

NADH

^
GTP

PEP

GDP

Figure 4: The PEPCK enzyme-coupled assay. The generation of OAA
from malate via MDH provides PEPCK with the necessary substrate to synthesize PEP.
One hundred and twenty ul of liver cytosol fraction was added and allowed to equilibrate
in a 37°C water bath for an additional one minute. To start the reaction, 1 mM GTP was
added

with

a

final

volume

of

2

ml.

NADH

formation

was

measured

spectrophotometrically at 340 nm. The assay was performed in duplicate for each amount
of malate. The assay was programmed to run for 15 seconds / cycle for an average of 4
minutes (-16 cycles).
Beer's law was used to determine the activity (velocity, v) of PEPCK (A= Ebc).
'A' is the change in OD, 'E' is the extinction coefficient of NADH (6200 L/ (mol x cm),
'b' is the path length of the cuvette (1 cm) and 'c' is the concentration (mol/L). The
following equations were used to normalize for the amount of protein (umol / min / mg
protein) and the amount of liver (umol / min / g wet weight liver).
Protein:
(Average A/min)
/
\
L V 6200 L/(mol x cm) /
r

x10 6 umol/mol

J

f /• Average protein cone, mg/ml \

IA

-,
x 0.002 L

1000ul/ml
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120 ul 1

Liver:

[

(Average A/mirt)

-,

/
\ X 10 6 umol/mol x
V 6200 L/(mol x cm) /
Ys
[liver (g) / buffer (ml)]
\
x

L

1000ul/ml

0.002 L
J
12o

ul "l

J
Solutions

Stock Solution of 100 mM Tris. pH 8.0
•

The solution was prepared by placing 1.211 g of Tris (FW: 121.1) in 80 ml of
ddH 2 0. pH was adjusted to 8.0 with HC1 and the final volume was brought to 100
ml. The solution was stored at 4°C.

Stock Solution of 5 mM MnCl?
•

The solution was prepared by placing 0.0989 g of MnCl2 (FW: 197.9) in ddH 2 0
with the final volume being brought to 100 ml. The solution was stored at 4°C.

Stock Solution of 10 mM NAD+
•

The solution was prepared by placing 0.1326 g of NAD+ (FW: 663.4) in 20 ml of
ddH 2 0. The solution was mixed thoroughly and then aliquoted into cryovials in
the amount of 500 \i\ and stored at -20°C.

Stock Solution of 1:500 dilution of MDH (Sigma Aldrich. 2.2 me/ml)
•

Ten \x\ of MDH was placed into 490 \K\ of 0.9% NaCl. Mixture was made fresh
for each assay and kept on ice for the duration of the experiment.

0.9% NaCl:
•

The solution was prepared by dissolving 0.9 grams of NaCl in ddH20 and the
volume was brought to 100 ml. The solution was stored at 4°C.
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Stock Solution of 10 mM Malate
•

The solution was prepared by placing 0.0356 g of malate (FW: 178.05) in 20 ml
of ddH20. The solution was stored at 4°C.

Stock Solution of 20 mM Malate
•

The solution was prepared by placing 0.0712 g of malate (FW: 178.05) in 20 ml
of ddH20. The solution was stored at 4°C.

Stock Solution of 10 mM GTP
•

The solution was prepared by placing 0.1046 g of GTP (FW: 523.2) in 20 ml of
ddH20. The solution was mixed thoroughly and then aliquoted into cryovials in
the amount of 500 ul and stored at -20°C.

Table 1: Assay Cuvette
0 mM malate

4 mM malate

12.5 mM Tris

250 ul

100 mM Tris

250 ul

0.75 mM MnCl 2
1 mM NAD +

300 ul
200 ul
50 ul

5 mM MnCl 2
10mMNAD
1:500 MDH

300 ul
200 ul

1 mM GTP
10 mM malate

200 ul

lOmMGTP

Oul

ddH 2 0
liver cytosol

1:500 MDH

+

50 ul

8 mM malate
100 mM Tris
5 mM MnCl 2
10mMNAD+
1:500 MDH
lOmMGTP

250 ul
300 ul
200 ul
50 ul

10 mM malate

200 ul
800 ul

20 mM malate *

200 ul
800 ul

880 ul

ddH 2 0

80 ul

ddH 2 0

80 ul

120 ul

liver cytosol

120 ul

liver cytosol

120 ul

Table 1: Examples of solution amounts added to assay cuvette. Water amount changed
with corresponding malate amount. A 20 mM concentration of malate was used for 8 mM
cuvette in order to maintain a final volume of 2 ml.
Statistics
Statistical analysis was performed on JMP 8.0 software. A two-way ANOVA general linear model analysis was performed using PBDE treatment and time as main
effects and PBDE treatment x time as a covariate. Significance was set as p < 0.05.
Outliers

were

excluded

using

a

Q-test
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(Fritz

and

Schenk

1969).

CHAPTER III

THE EFFECT OF IN VIVO PBDE TREATMENT ON
HEPATIC PHOSPHOENOLPYRUVATE CARBOXYKINASE
ENZYME KINETICS
IN MALE WISTAR RATS

INTRODUCTION
Phosphoenolpyruvate carboxykinase (PEPCK) is a key regulatory enzyme in
gluconeogenesis (GNG) that converts oxaloacetate to phosphoenolpyruvate and is
dependent on guanosine triphosphate (GTP)- or inosine triphosphate (ITP)-. PEPCK is
present in the liver, kidney, lung, heart, small intestine and adipose tissue and resides in
both the mitochondria and cytosol of most mammals, although its distribution varies. For
example, in humans, 60% of PEPCK is found in the mitochondria with 40% in the
cytosol. In rats, only 10% is found in the mitochondria while 90% is in the cytosol
(Hanson and Garber 1972; Hanson and Reshef 1997)
Cytosolic PEPCK (PEPCK-C) is highly regulated by diet and hormones including
thyroid, glucagon, glucocorticoids and insulin. (Ballard and Hanson 1969; Hanson and
Reshef 1997) The gene for PEPCK-C is regulated at the transcriptional level via
induction and repression. During times of starvation, PEPCK-C is induced and
consumption of a high carbohydrate diet will reduce synthesis. Glucagon, a hormone
released during times of low blood sugar, and thyroid hormone both increase PEPCK-C
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synthesis while insulin, released during times of high blood sugar, inhibits gene synthesis
(Ballard and Hanson 1967; Gurney et al. 1994; Hanson and Reshef 1997).
Studies have been conducted examining effects of xenobiotics on hepatic GNG
and PEPCK. Phenobarbital (PB) exposure of rats inhibited hepatocyte glucose production
and PEPCK activity by 50% (Argaud et al. 1991). Chauvin et al. (1996) found PEPCK
enzyme kinetics from PB-treated rats decreased Vmax and Km by about 50% and 30%,
respectively (Chauvin et al. 1996). Following exposure to 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD), male rats had a 50% decrease of PEPCK activity at the highest dose and
female rats had a 25% decrease. Plasma glucose levels were also slightly decreased
compared to controls (Viluksela et al. 1999). A 55% reduction of plasma glucose and a
66% reduction of PEPCK activity were also observed in fish following exposure to a
polychlorinated biphenyl mixture (Vijayan et al. 2006).
Another class of xenobiotic is polybrominated diphenyl ethers (PBDEs). PBDEs
are a family of lipophilic, flame retardant chemicals introduced in the 1970's. PBDEs are
used in consumer products including plastics, electronics, furniture and carpeting to slow
the rate at which products burn (Darnerud et al. 2001). PBDEs are only mixed with the
polymer resin. Therefore, as products break down, PBDEs have the ability to leach into
the environment because they are not chemically bound to the product (Darnerud et al.
2001; Kim et al. 2006; McDonald 2002). Since PBDEs are resistant to chemical and
physical breakdown, they can bioaccumulate in the environment and even biomagnify
within the food chain (Alaee and Wenning 2002; Costa et al. 2008; Hale et al. 2003).
PBDEs have been found in soil sediment, marine animals, fish-eating birds, dairy
products, and human breast milk, serum and adipose tissue (Andersson and Blomkviet
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1981; Dunn et al. 2010; Inoue et al. 2006; Jansson et al. 1987; Lorber 2008; Petreas et al.
2003; Schecter et al. 2010; Schecter et al. 2003; Stafford 1983; Watanabe et al. 1987).
Moreover, PBDEs are classified as an endocrine disrupting chemical as they have been
shown to alter thyroid and estrogen family hormone homeostasis (Hallgren and Darnerud
2002; Zhou et al. 2001; Zhou et al. 2002). A disruption in insulin stimulated glucose
metabolism was also observed in adipocytes isolated from in vivo PBDE treatment of rats
(Hoppe and Carey 2007). The effect of PBDE treatment on PEPCK activity is unknown.
The purpose of this study was to determine the effect of in vivo PBDE treatment
of rats on hepatic PEPCK activity and fasting plasma glucose and insulin. Our hypothesis
was that hepatic PEPCK activity is reduced by in vivo PBDE treatment of rats.
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MATERIALS AND METHODS

Animals
Forty-eight male Wistar rats, (Charles River Laboratory, Wilmington, MA) were
used for this study. All rats weighed between 75-100 grams upon arrival. The rats were
housed under controlled pressure and a 12- hour light/dark cycle. They were fed standard
chow and water ad libitum. The University of New Hampshire's Animal Care and Use
Committee approved all procedures, #110406.
Treatment
The rats were allowed to adjust to their new habitat for five days prior to the start
of treatment. The rats were randomly assigned to two different gavage treatments: 14 mg
PBDE / kg body weight / day (n = 24) or corn oil control (n = 24). Rats were gavaged
daily, generally between 8 and 9 am. Initial body weights were obtained at the onset of
treatment and body weight was recorded three times per week. Rats were euthanized after
a 16 - hour fast at 3, 14 and 28 days of treatment (n = 8), using carbon dioxide gas.
Preparation of Blood and Liver Samples
Blood
Approximately 5 ml of blood was obtained via cardiac puncture using a 0.2%
EDTA rinsed 18G-1.5" needle and a 5 ml syringe. Blood was transferred to a 6 ml EDTA
- treated tube (Thermo Fisher Scientific, Waltham, MA) and kept on ice until it was
transported back to the lab. Once in the lab, the collected blood was centrifuged at 3000
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rpm for 15 minutes at 4°C in an IEC - Centra8R centrifuge. Approximately 1-2.5 ml of
plasma was removed, aliquoted into cryovials in the amount of 250 - 400 ul, frozen and
stored at -80°C.
Liver
The liver was removed, weighed, cut into approximately two-gram portions, flash
frozen in liquid nitrogen, wrapped in aluminum foil and stored at -80°C.
Preparation of Liver Cytosol Fraction
Liver cytosol fraction was prepared as described by Chauvin et al. (1996) with the
following additional details. A liver portion was thawed, weighed (approx. 2 g), minced
with scissors and placed in nine volumes of working homogenizing solution. Tissue was
then homogenized for 15 seconds using a Powerstat® polytron (Thermo Fisher
Scientific, Waltham, MA) at a setting of 60.
Analysis of Blood and Liver
Blood Analysis
Blood was analyzed for fasting glucose (glucose oxidase kit, Sigma-Aldrich);
insulin and C-peptide (ELISA and RIA kits, respectively, Millipore), according to
manufacturer' s instructions.
Liver Cytosol Fraction
The liver cytosol was used for a phosphoenolpyruvate carboxykinase (PEPCK)
enzyme-coupled assay, which was performed with modifications, as described by
Chauvin et al. (1996). The enzyme-coupled assay utilizes malate dehydrogenase (MDH)
to convert malate to oxaloacetate

(OAA). PEPCK then converts OAA to
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phosphoenolpyruvate (PEP). MDH requires nicotinamide adenine dinucleotide (NAD )
as a coenzyme resulting in the generation of the reduced form of nicotinamide adenine
dinucleotide (NADH), which can be measured spectrophotometrically at 340 nm.
A 3-ml acrylic cuvette contained the following with a final volume of 2 ml: 12.5
mM Tris, pH 8.0; 0.75 mM MnCl2; 1 mM NAD+; 6 U of malate dehydrogenase and
varying concentrations of malate ( 0 - 8 mM). The mixture was allowed to equilibrate in a
37°C water bath for three minutes. One hundred and twenty ul of liver cytosol fraction
was added and allowed to equilibrate in a 37° C water bath for an additional one minute.
To start the reaction, 1 mM GTP was added. NADH formation was measured
spectrophotometrically at 340 nm at 23°C. The assay was performed in duplicate for each
concentration of malate.
In order to normalize Vmax for mg of protein, total protein concentration of the
cytosol was measured via a commercial DC protein assay (BioRad).
Statistics
Statistical analysis was performed on JMP 8.0 software. A two-way ANOVA general linear model analysis was performed using PBDE treatment and time as main
effects and PBDE treatment x time as a covariate. Significance was set as p < 0.05.
Outliers were excluded using a Q-test (Fritz and Schenk 1969).
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RESULTS

Animal Measurements
Final body weight, weight gain over the treatment period, final liver weight and
liver as a percent of body weight are represented as mean ± SEM at days 3, 14 and 28
(Table 2). There was a significant effect of time (p < 0.05) on final body weight and the
effect of PBDE treatment on final body weight was approaching significance (p = 0.07).
There was a significant effect of time (p < 0.05), but not treatment, on weight gain over
the treatment period. Final liver weight was not different between control and treatment
but liver weight as a percent of body weight was significantly higher in PBDE-treated
rats compared to control (p < 0.05).
In order to compare the effect of treatment on liver weight as a function of time,
data for liver weight and liver weight as a percent of body weight are displayed in Figure
5 and 6. There was a significant effect of time (p < 0.05) on final liver weight (Figure 5).
Liver weight as a percent of body weight was higher in the PBDE group with an effect of
treatment (p < 0.05) and time (p < 0.05) (Figure 6). The slopes of the control and
treatment trendlines are similar (m = -0.023 and m = -0.022, respectively) indicating the
effect of treatment was independent of time.
PEPCK Enzyme Kinetics
Velocity versus substrate concentration plots for PEPCK (Figures 7 - 9 ) are
expressed as the mean of 8 experiments ± SEM; plots follow standard Michaelis-Menton
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kinetics. Each individual velocity vs. substrate curve was fit via SigmaPlot 10 to generate
Km and Vmax values; data for 8 replicates at each time point and treatment are
represented as mean ± SEM in Table 3. There was no effect of treatment or time on Km
values. Vmax values, normalized for protein, were 26%, 44% and 43% lower on average
in the treatment group, compared to control at 3, 14 and 28 days, respectively, with an
effect of treatment (p < 0.05) and time (p < 0.05) (Figure 10). The effect of treatment
was independent of time as the slopes of trendlines for control and treatment are similar
(m = -0.0003 and m = -0.0004, respectively). Similar results were seen when Vmax
values were normalized for liver weight (Figure 11). The effect of treatment was
independent of time, however, the three-fold difference of control and treatment trendline
slopes (m = -0.0077 and m = -0.0229, respectively) suggested a treatment x time
interaction (p = 0.11). Vmax values, expressed as total liver PEPCK activity, were 18%,
34% and 41% lower on average in the treatment group compared to control at 3, 14 and
28 days, respectively, with an effect of treatment (p < 0.05), time (p < 0.05) and an
interaction effect (p < 0.05) (Figure 12).
Blood Measurements
Fasting glucose, insulin and C-peptide are represented as mean ± SEM in Table 4.
There was no effect of treatment on any of the values. In order to compare the effect of
treatment on glucose, insulin and C-peptide as a function of time, data for each value
displayed in Figure 13, 14 and 15. There was a significant effect of time (p < 0.05) for
fasting glucose but no significant effect of treatment (Figure 13) and fasting insulin
(Figure 14). By 28 days, insulin values of the PBDE treatment group were trending to
lower values compared to control but this apparent interaction was not significant (p =
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0.17) (Figure 15). This response was mimicked by the C-peptide values; by 28 days, Cpeptide values of the treatment group were trending towards lower values compared to
control (Figure 15), with an effect of time (p < 0.05) but the interaction effect was not
significant (p = 0.13).

34

Table 2: Body Weight, Weight Gain and Liver Weight at 3,14 and 28 days of treatment
Final body weight (g)

Weight gain (g)

Final liver weight (g)

Liver weight as % of BW (%)

Time
(Days)

Control [CI

Treatment [Tl

C

T

C

T

C

T

3

142.9 ±4.2

141.3 ±1.7

20.0 ±0.8

17.3 ±0.7

6.38 ±0.21

6.73 ±0.2

4.47 ±0.11

4.77 ±0.16

14

221.4 ±4.4

213.0 ±5.6

81.9 ±3.1

78.1 ±4.5

9.71 ±0.31

10.08 ±0.29

4.4 ±0.15

4.73 ±0.05

28

316.0 ±6.5

305.6 ±3.6

171.3 ±5.5

168.5 ±3.4

12.33 ±0.38

12.93 ±0.42

3.9 ±0.1

4.22 ±0.1

Table 2: Animal measurements represented as mean ± SEM (n = 8 per group). Final weight and weight gain was similar among
PBDE-treated group and control, both with an effect of time (p < 0.05). Liver weights were not different between control and PBDEtreated group, but there was a significant effect of time (p < 0.05). Final liver weight expressed as a percent of body weight was higher
in PBDE-treated group with an effect of treatment (p < 0.05) and time (p < 0.05).

Figure 5: Final liver weight at 3, 14 and 28 days of treatment
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Figure 5: Final liver weight measured at 3, 14 and 28 days. There was an effect of time
(p < 0.05).
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Figure 6: Liver Weight as Percent of Body Weight at 3,14 and 28 days of treatment
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Figure 6: Liver weight expressed as a percent of body weight. Liver weight as a percent
of body weight was higher in the PBDE group with an effect of treatment (p < 0.05) and
time (p < 0.05).
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Figure 7: 3 day PEPCK, velocity vs. substrate curves, expressed per mg protein and
per gram liver
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Figure 7: A: PEPCK activity at 3 days, normalized for mg protein for control ( • )
animals vs. treatment (•) animals (n = 8, mean ± SEM). B: PEPCK activity at 3 days
normalized for gram of liver for control ( • ) animals vs. treatment (•) animals (n = 8,
mean ± SEM).
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Figure 8: 14 day PEPCK, velocity vs. substrate curves, expressed per mg protein
and per gram liver
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Figure 8: A: PEPCK activity at 14 days, normalized for mg protein for control ( • )
animals vs. treatment (•) animals (n = 8, mean ± SEM). B: PEPCK activity at 14 days
normalized for gram of liver for control ( • ) animals vs. treatment (•) animals (n = 8,
mean ± SEM).
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Figure 9: 28 day PEPCK, velocity vs. substrate curves, expressed per mg protein
and per gram liver
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Figure 9: A: PEPCK activity at 28 days, normalized for mg protein for control ( • )
animals vs. treatment (•) animals (n = 8, mean ± SEM). B: PEPCK activity at 28 days
normalized for gram of liver for control ( • ) animals vs. treatment (•) animals (n = 8,
mean ± SEM).
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Table 3: PEPCK Enzyme Kinetics at 3,14 and 28 days of treatment

Km [malatel (mM)

-p*

Vmax (umol/min/mg protein)

Vmax (umol/min/g liver
weight)

Total PEPCK Activity
(nmol/min/liver)

Time
(Days)

Control rCl

Treatment 1T1

C

T

C

T

C

T

3

3.89 ±0.77

4.67 ±0.98

0.023 ±0.003

0.017 + 0.002

2.2 ±0.18

1.71 ±0.12

14.1 ±1.32

11.4 ±0.67

14

4.63 ±0.42

3.8 + 0.24

0.016 ±0.001

0.009 ±0.001

1.92 ±0.11

1.23 ±0.05

18.7 ±1.3

12.4 ±0.5

28

4.17 ±0.5

5.72 ±0.88

0.014 ±0.001

0.008 ±0.001

1.99 ±0.09

1.12 ±0.09

24.6 ±1.28

14.6 ±1.46

Table 3: Curve fitting and calculation of PEPCK enzyme kinetics, Km and Vmax, was performed on SigmaPlot 10 shown as mean ±
SEM at days 3, 14 and 28 (n = 8 per group). Km values were similar between the two groups. Vmax values, regardless of units
expressed, all had an effect of time (p < 0.05) and an effect of treatment (p < 0.05). Vmax, normalized for g liver weight, had an
interaction effect approaching significance (p = 0.11). Total PEPCK activity had a significant interaction effect (p < 0.05).

Figure 10: PEPCK Vmax (u.mol/min/mg protein) at 3,14 and 28 days of treatment
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Figure 10: Vmax values, normalized for protein, were lower in the treatment group with
an effect of treatment (p < 0.05) and time (p < 0.05). The effect of treatment was
independent of time as the slopes of trendlines for control (m = -0.0003) and treatment (m
= - 0.0004) are similar.
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Figure 11: PEPCK Vmax (u.mol/min/g liver weight) at 3, 14 and 28 days of
treatment
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Figure 11: Vmax values, normalized for liver weight, were lower in the treatment group
with an effect of treatment (p < 0.05) and time (p < 0.05). The effect of treatment was
independent of time. The three-fold difference of trendline slopes, control m = -0.0077
and treatment m = -0.0229, suggests a treatment x time interaction (p = 0.11).
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Figure 12: Total PEPCK Activity at 3,14 and 28 days of treatment
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Figure 12: Velocity values, normalized for total PEPCK activity, were lower in the
treatment group with an effect of treatment (p < 0.05), time (p < 0.05) and an interaction
effect (p < 0.05).
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Table 4: Fasting plasma glucose, insulin and C-peptide at 3,14 and 28 days of treatment
Fasting Glucose (mg/dl)

C-peptide (pM/0.1 ml)

Insulin (ng/ml)

Time
tDavs)

C

T

C

T

C

T

3

89.33 ±4.23

93.43 ± 6.73

0.226 ±0.019

0.208 + 0.029

232.4 ±33.19

231.9 ±34.89

14

148.64 ±12.59

153.81 ± 10.06

0.237 ±0.016

0.274 + 0.032

369.9 ±49.58

402.6 ±43.01

28

184.36 ±7.88

200.47 ±8.17

0.572 ± 0.043

0.434 + 0.075

698.3 ±47.32

555.3 ± 74.06

Table 4: Fasting plasma glucose, insulin and C-peptide are represented as mean ± SEM (N = 8 per group). There was no significant
effect of treatment on glucose, insulin or C-peptide levels.

Figure 13: Fasting plasma glucose at 3, 14 and 28 days of treatment
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Figure 13: Plasma glucose following 16-h fast. There was a significant effect of time (p
< 0.05) for fasting glucose but no significant effect of treatment.
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Figure 14: Plasma Insulin at 3,14 and 28 days of treatment
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Figure 14: There was an effect of time (p < 0.05) for insulin levels. The interaction effect
was not significant (p = 0.17) despite dissimilar slopes (control m = 0.014, treatment m =
0.0091).
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Figure 15: Plasma C-peptide at 3,14 and 28 days
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Figure 15: There was an effect of time (p < 0.05) for C-peptide. The interaction effect
was not significant (p = 0.13) despite dissimilar slopes (control m = 18.73, treatment m =
12.848).
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DISCUSSION

This study is the first to investigate the effects of in vivo PBDE treatment on
hepatic phosphoenolpyruvate carboxykinase (PEPCK) enzyme kinetics. We hypothesized
that hepatic PEPCK activity would be reduced by in vivo PBDE treatment of rats. Our
findings support this hypothesis and demonstrate that PBDEs disrupt PEPCK enzyme
kinetics.
First, we provide evidence of a reduction in PEPCK Vmax after 3 days of PBDE
treatment that persisted through 28 days. To our knowledge, four papers exist that have
investigated the effect of xenobiotic exposure on hepatic PEPCK. Our findings are
similar to work by Argaud et al. (1991) and Chauvin et al. (1996) who exposed rats to
100 mg/kg/day of Phenobarbital for two weeks and found a 50% decrease of PEPCK
Vmax, expressed as umol/min/g liver wet weight. We found a 40% reduction in Vmax
(umol/min/g liver wet weight) in the treatment group compared to control at 14 days. The
researchers also found a 30% decrease in Km in treatment rats compared to control
(Argaud et al. 1991; Chauvin et al. 1996) In contrast to their findings, we found there was
no disruption of PEPCK Km. This observation in combination with the reduction in
Vmax, suggests a disruption in transcription and/or translation of the PEPCK gene or
protein, respectively. This would need to be confirmed by determining protein levels of
PEPCK following PBDE treatment. Our findings are also consistent with work by
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Viluksela et al. (1999) who exposed rats to a range of 50-9600 u.g/kg of TCDD for 10
days and found a maximum Vmax reduction of 50% with the highest dose in male rats
compared to control (Viluksela et al. 1999). Vijayan et al. (2006) also found a 66%
reduction of PEPCK activity in the treatment group compared to control Anadromous
arctic char following exposure to 100 mg/kg of Aroclor 1254 (Vijayan et al. 2006).
Second, we examined the physiological effects of PBDE treatment on glucose
metabolism by analyzing fasting glucose, insulin and C-peptide values. Despite the
decrease in PEPCK Vmax, we found fasting glucose was not impacted by PBDE
treatment. This is consistent with the work of She et al. (2003) using liver PEPCKknockout mice. The liver PEPCK-knockout mice maintained fasting blood glucose levels
that were similar or even higher than control. She et al. (2003) suggest that this
maintenance of blood glucose levels could be attributed to an up-regulation of
gluconeogenesis in extrahepatic tissues such as the kidney (She et al. 2003). Work by
Hakimi et al. (2005) confirms the importance of PEPCK in the kidney. Hepatic and
kidney PEPCK knockout mice did not gain weight one day after birth, had 60% lower
glucose levels, twice the level of triglycerides in the blood and liver and three times the
level of ketone bodies compared to control (Hakimi et al. 2005).
Our findings are in contrast to Viluksela et al. (1999) who saw a decrease in
plasma glucose of treatment rats exposed to TCDD compared to control and Vijayan et
al. (2006) who, in addition to a reduction of PEPCK Vmax, also found a 55% reduction
of plasma glucose in fish following exposure to PCB. These discrepancies are most likely
due to using different species models (fish vs. rat), different chemicals (TCDD or PCB
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vs. PBDE), different dosages (9600 u,g/kg TCDD or 100 mg/kg PCB vs. 14 mg/kg DE71) and different time periods (10 days or 4 months vs. 28 days).
Unpublished work done in our lab found insulin was 30% lower after 28 days of
PBDE treatment compared to control, although this was not statistically significant (p =
0.075) (Allgood 2009). Allgood used the same dose of DE-71 for the same length of time
and the same species of Wistar rat. Although the treatment effect was also not significant
in our work, we found a 24% decrease in insulin at 28 days. It is possible that this
decrease could be exacerbated by treatment time.
There are several possible mechanisms by which PBDE exposure could affect
PEPCK activity. First, it is known that PBDE exposure decreases thyroid hormone, T4, in
rats (Hallgren and Darnerud 2002; Zhou et al. 2001; Zhou et al. 2002). Thyroid hormone
normally diffuses through the nucleus and binds to its nuclear receptor (NR). The NRthyroid hormone complex will then bind to the thyroid response element on the PEPCK
gene promoter (Yabaluri and Bashyam 2010). Therefore, PEPCK gene promotion could
be reduced due to low levels of thyroid hormone. Another possible mechanism is via
another nuclear receptor, pregnane X receptor (PXR). It is known that PBDEs are a
ligand to PXR (Fery et al. 2009; Pacyniak et al. 2007). It is also known that activated
PXR results in a reduced gene expression of PEPCK (Bhalla et al. 2004; Zhou et al.
2006) via direct interaction with the forkhead transcription factor, FOXOl, a PEPCK
gene activator (Kodama et al. 2004). Therefore, a plausible mechanism of action is that
PBDE exposure activates PXR, inhibiting FOXOl from binding to the response element
on the PEPCK gene promoter, causing a reduction in PEPCK gene and, ultimately, a
reduction in PEPCK activity. This mechanism, however, requires validation.
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The decreased activity of PEPCK combined with unaffected levels of glucose and
a tendency toward lower levels of insulin following exposure to PBDEs suggests mild
glucose metabolism disruption in rats. There is very limited evidence that this disruption
occurs in humans. In 2008, a cross-sectional study using NHANES data examined the
correlation between diabetes and serum levels of brominated flame retardant. There was a
significant positive correlation between polybrominated biphenyl-153 (PBB-153) and
diabetes (defined as fasting glucose levels of >126 mg/dL and non-fasting glucose levels
of >200 mg/dL) and a monotonic association between PBDE-153 and diabetes (Lim et
al. 2008). Correlation does not mean causation, however, and further investigation is
warranted to determine if environmental chemicals are contributing to the diabetes
epidemic occurring in the United States.
Our findings, in combination with existing literature, confirm that exposure to
xenobiotics such as PB, PCB and PBDEs affect glucose metabolism by decreasing
PEPCK activity and, in some cases, altering plasma glucose and insulin levels. Future
work should focus on the mechanism of this disruption by examining protein and mRNA
expression of PEPCK following PBDE exposure to determine if the disruption occurs at
the transcriptional and/or translational level.
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APPENDIX A
Figure 1: Effect of PBDE treatment on cytochrome P450 enzymes: CYPl A, -3A and
2B.
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This series of experiments examined the effect of in vivo PBDE exposure of rats
on cytochrome P450 (CYP) enzyme activity. In summer of 2010, sixteen male Wistar
rats were gavaged with two types of treatment: corn oil or corn oil with 14 mg/kg PBDE
for 28 days. They has access to food from 8 AM to 5 PM and water ad libitum.
Approximately 1.5 g of liver from animals were sent to North Carolina for CYP activity
analysis. CYP activity was measured via a fluorometric assay as described previously
(Szabo et al. 2009). CYP activity was significantly induced by treatment compared to
control (* p < 0.05 compared to control). CYPl A was induced in the treatment group by
95%, CYP3A by 99% and CYP2B by 94% on average compared to control.
These data confirm that PBDE exposure induces hepatic CYP activity in rats.
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